Mi a EQRx, Inc. (EQRX piaci tőkésítése)

EQRx, Inc. piaci tőkésítése (EQRX) $728.90M

EQRx, Inc. (EQRX) Osztalékhozam

EQRx, Inc. is a U.S.-based pharmaceutical firm dedicated to innovating therapies, predominantly for oncological (cancer) and immune-inflammatory conditions. The company's late-stage pipeline features two promising drug candidates in Phase III clinical trials: Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor specifically for patients with EGFR-mutated non-small cell lung cancer (NSCLC), and Sugemalimab, an anti-programmed death-ligand 1 antibody aimed at treating Stage III and Stage IV NSCLC. Its broader developmental portfolio encompasses a range of additional clinical and pre-clinical assets. This portfolio includes Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor in Phase II trials for metastatic breast cancer; EQ176, an anti-programmed death-1 antibody undergoing Phase III development for primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor currently in various Phase I studies. Established in 2019, EQRx maintains its corporate headquarters in Cambridge, Massachusetts.

Év	Osztalékhozam	Változtassa meg
Nincs elég adat a megadott dátumokhoz.

Év

Osztalékhozam

Változtassa meg

Nincs elég adat a megadott dátumokhoz.

Vállalat	Osztalékhozam	Ország
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
CSL Limited CSL.AX	3.12%	AU
Moderna, Inc. MRNA.US	0.00%	US
Lonza Group AG LONN.SW	0.00%	CH

Vállalat

Osztalékhozam

Ország

Vertex Pharmaceuticals Incorporated

VRTX.US

0.00%

Argenx SE

ARGX.US

0.00%

CSL Limited

CSL.AX

3.12%

Moderna, Inc.

MRNA.US

0.00%

Lonza Group AG

LONN.SW

0.00%

EQRx, Inc.

EQRX

Kategória